Patents Assigned to Regeneron Pharmacuticals, Inc.
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 7608261
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: October 27, 2009
    Assignee: Regeneron Pharmacuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth S. Graham, Kelly Frye